Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021226560 - ANTIBODIES AGAINST SARS-COV-2

Publication Number WO/2021/226560
Publication Date 11.11.2021
International Application No. PCT/US2021/031442
International Filing Date 07.05.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • VIR BIOTECHNOLOGY, INC. [US]/[US]
  • HUMABS BIOMED SA [CH]/[CH]
  • CORTI, Davide [CH]/[CH]
  • PIZZUTO, Matteo [CH]/[CH]
  • PINTO, Dora [CH]/[CH]
  • BELTRAMELLO, Martina [CH]/[CH]
  • DE MARCO, Anna [CH]/[CH]
  • CAMERONI, Elisabetta [CH]/[CH]
  • SNELL, Gyorgy [US]/[US]
  • CZUDNOCHOWSKI, Nadine [US]/[US]
  • HAVENAR, Colin [US]/[US]
  • LEMPP, Florian [US]/[US]
  • TELENTI, Amalio [US]/[US]
Inventors
  • CORTI, Davide
  • PIZZUTO, Matteo
  • PINTO, Dora
  • BELTRAMELLO, Martina
  • DE MARCO, Anna
  • CAMERONI, Elisabetta
  • SNELL, Gyorgy
  • CZUDNOCHOWSKI, Nadine
  • HAVENAR, Colin
  • LEMPP, Florian
  • TELENTI, Amalio
Agents
  • MORGAN, John, A.
  • OBEIDAT, Baha, A.
  • ADRA, Bilal H.
  • KUMABE, Blake, K.
  • SAHACHARTSIRI, Bobby
  • SOLTANI, Bobby, B.
  • ZENTZ, Bradley, J.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • ROTH, Carol, J.
  • EIDT, Chandra, E.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • CONLEE, David, C.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • GERTZ, Glenda, A.
  • HAN, Hai
  • TALBERT, Hayley, J.
  • KHANNA, Hemant
  • BARRETT, Jared, M.
  • DANLEY, Jeffrey, E.
  • SAKOI, Jeffrey, M.
  • SEO, Jeong Hee
  • BAUNACH, Jeremiah, J.
  • ZHANG, Jianping
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • COOPER, Michael, P.
  • LECOINTE, Michelle M.
  • BENDEMIRE, Paul, D.
  • LIN, Qing
  • HALLER, Rachel, A.
  • WEBB, Samuel, E.
  • LIU, Shi
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • LAWRENZ, Steven, D.
  • ABEDI, Syed
  • SHEWMAKE, Thomas, A.
  • BOLLER, Timothy, L.
  • LIGON, Toby, J.
  • LI, Yiheng
  • SAKOI, Zachary, M.
Priority Data
63/022,39208.05.2020US
63/024,37213.05.2020US
63/027,81420.05.2020US
63/029,33822.05.2020US
63/031,28628.05.2020US
63/033,04501.06.2020US
63/036,68309.06.2020US
63/039,93916.06.2020US
63/046,46530.06.2020US
63/057,76728.07.2020US
63/090,66712.10.2020US
63/113,45013.11.2020US
63/153,78425.02.2021US
63/170,36802.04.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES AGAINST SARS-COV-2
(FR) ANTICORPS CONTRE SARS-COV-2
Abstract
(EN) The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of potently neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode antibodies and antigen-binding fragments, vectors, host cells, and related compositions and uses, including for preventing, treating, and diagnosing an infection by SARS-CoV-2 or another coronavirus.
(FR) La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier à un antigène du SARS-CoV-2 et, dans certains modes de réalisation, peuvent neutraliser puissamment une infection par SARS-CoV-2. La divulgation concerne également des polynucléotides qui codent pour des anticorps et des fragments de liaison à l'antigène, des vecteurs, des cellules hôtes, et des compositions et des utilisations associées, notamment pour la prévention, le traitement et le diagnostic d'une infection par SARS-CoV-2 ou un autre coronavirus.
Latest bibliographic data on file with the International Bureau